Search
Biospace news
RSS Feed for Biotech, Pharmaceutical and Clinical Research News | BioSpace (Generated by New Sloth)
Updated: 10 hours 55 min ago
Poor Customer Data Management Costs Pharma Companies Money: Report
Poor Customer Data Management Costs Pharma Companies Money: Report 4/10/2024
AACR 2024: What Cancer Researchers Are Talking About
AACR 2024: What Cancer Researchers Are Talking About 4/10/2024
Pfizer Eyes Broader Label for RSV Vaccine Abrysvo After Promising Phase III Data
Pfizer Eyes Broader Label for RSV Vaccine Abrysvo After Promising Phase III Data 4/9/2024
Nvelop and Seaport Raise $100M in Rounds, Tap Bluebird and Karuna Execs
Nvelop and Seaport Raise $100M in Rounds, Tap Bluebird and Karuna Execs 4/9/2024
FDA Backs BrainStorm’s Design for Phase IIIb Trial in Early-Stage ALS
FDA Backs BrainStorm’s Design for Phase IIIb Trial in Early-Stage ALS 4/9/2024
EMA to Review Diabetes and Weight-Loss Drugs for Suicidal Ideation Risk
EMA to Review Diabetes and Weight-Loss Drugs for Suicidal Ideation Risk 4/9/2024
AbbVie’s Humira Loses Only 4% of Market Share to Biosimilars: Report
AbbVie’s Humira Loses Only 4% of Market Share to Biosimilars: Report 4/9/2024
Merck, Essential Pharma, CoreRx and More Continue 2024 M&A Upswing
Merck, Essential Pharma, CoreRx and More Continue 2024 M&A Upswing 4/9/2024
Merck Snaps Up Small Startup in $208M Deal, Seeks to Improve Safety of ADCs
Merck Snaps Up Small Startup in $208M Deal, Seeks to Improve Safety of ADCs 4/8/2024
BMS Sees Early ROI for $14B Karuna Buy with Phase III Schizophrenia Win
BMS Sees Early ROI for $14B Karuna Buy with Phase III Schizophrenia Win 4/8/2024
ACC24 Roundup: Novo, Ionis Tout Cardio Victories and Boehringer, Lilly Disappoint
ACC24 Roundup: Novo, Ionis Tout Cardio Victories and Boehringer, Lilly Disappoint 4/8/2024
5 Successful Phase III Oncology Trials in Q1
5 Successful Phase III Oncology Trials in Q1 4/8/2024
The Next Wave of ADCs Could Treat Evasive Solid Tumors
The Next Wave of ADCs Could Treat Evasive Solid Tumors 4/8/2024
AstraZeneca, Daiichi Sankyo Win First Tumor-Agnostic HER2 FDA Approval for Enhertu
AstraZeneca, Daiichi Sankyo Win First Tumor-Agnostic HER2 FDA Approval for Enhertu 4/8/2024
FDA Again Rejects Supernus Drug-Device Combo for Parkinson’s Disease
FDA Again Rejects Supernus Drug-Device Combo for Parkinson’s Disease 4/8/2024
Opinion: The Next Generation of ADCs Will Improve Cancer Treatment
Opinion: The Next Generation of ADCs Will Improve Cancer Treatment 4/8/2024
FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple Myeloma Treatment
FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple Myeloma Treatment 4/6/2024
AstraZeneca’s Imfinzi Clinches Late-Stage Victory in Aggressive Lung Cancer
AstraZeneca’s Imfinzi Clinches Late-Stage Victory in Aggressive Lung Cancer 4/5/2024
Contineum Dials Back Plans with $110M IPO to Fund Neuroinflammatory Trials
Contineum Dials Back Plans with $110M IPO to Fund Neuroinflammatory Trials 4/5/2024
Networking, ADCs and Early Science on the Agenda at AACR 2024
Networking, ADCs and Early Science on the Agenda at AACR 2024 4/5/2024
World Pharma News
- How the Birmingham Drug Discovery Hub created an investment-ready 'drug library'
- Common HIV treatments may aid Alzheimer's disease patients
- AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson's disease
- Next-generation treatments hitch a ride into cancer cells
- Groundbreaking treatment approach shows promise in hard-to-treat cancers